Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475128 | 0.93 | USP2 (0.53) | USP2DNMT1TDP1L3MBTL1THRB | |
| SCHEMBL5473561 | 0.87 | ALDH1A1 (0.56) | USP2DNMT1TDP1L3MBTL1TP53 | |
| SCHEMBL3180194 | 0.85 | ADORA2A (0.71) | ADORA2A | |
| SCHEMBL5469709 | 0.84 | ADORA2A (0.71) | ADORA2A | |
| SCHEMBL3199843 | 0.81 | — | — | |
| SCHEMBL5473552 | 0.79 | — | — | |
| SCHEMBL5467829 | 0.77 | — | — | |
| SCHEMBL5466384 | 0.76 | — | — | |
| SCHEMBL5467800 | 0.76 | — | — | |
| SCHEMBL5468832 | 0.75 | ADORA2A (0.70) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | claimed |
| EP-1615931-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092177-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | USP2 2735/4885DNMT1 1125/4885TDP1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.